Physician profile
Brian T Mosrie
NPI 1124069554
$9,241.33
in general payments reported to CMS, 2019-2025
53 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $585 · 2021: $983 · 2022: $1,575 · 2023: $1,769 · 2024: $1,905 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,059.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,151.55 | 2019-2025 | |
| Novo Nordisk INC | $1,106.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,094.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $834.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.00 | 2019-2025 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.09 | 2019-2025 | Xifaxan |
| Amgen INC. | $438.96 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $423.07 | 2019-2025 | Airsupra, Farxiga, Enhertu |
| Janssen Pharmaceuticals, INC | $359.93 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $225.57 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $216.81 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $178.97 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $160.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $158.98 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $151.65 | 2023-2025 | Gvoke Hypopen |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mosrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.